Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes

[1]  R. Lazzara,et al.  Spontaneous Adverse Event Reports of Serious Ventricular Arrhythmias, QT Prolongation, Syncope, and Sudden Death in Patients Treated with Cisapride , 2002, Journal of cardiovascular pharmacology and therapeutics.

[2]  Sten Olsson,et al.  Spontaneous Reporting Systems Outside the US , 2002 .

[3]  P B Iannini,et al.  Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. , 2001, The Journal of antimicrobial chemotherapy.

[4]  M. Santini,et al.  Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. , 2000, European heart journal.

[5]  P. Vardas,et al.  Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. , 2000, Chest.

[6]  R. Lazzara,et al.  Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride: An ongoing independent case review , 2000 .

[7]  S. Ayis,et al.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients , 2000, The Lancet.

[8]  P. Chue,et al.  Antipsychotic agents and QT changes. , 2000, Journal of psychiatry & neuroscience : JPN.

[9]  L. Biblo,et al.  Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. , 2000, The American journal of emergency medicine.

[10]  P. Bernink,et al.  Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial. , 2000, Circulation.

[11]  T. Lherm,et al.  [Torsade de pointes after poisoning with fluoxetine alone]. , 2000, Presse medicale.

[12]  C. Keller,et al.  Sevoflurane, but not Propofol, Significantly Prolongs the Q-T Interval , 2000, Anesthesia and analgesia.

[13]  H. Lamb,et al.  Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. , 2000, Drugs.

[14]  C. January,et al.  Droperidol Lengthens Cardiac Repolarization due to Block of the Rapid Component of the Delayed Rectifier Potassium Current , 1999, Journal of cardiovascular electrophysiology.

[15]  L. Mandell,et al.  Comparative Tolerability of the Newer Fluoroquinolone Antibacterials , 1999, Drug safety.

[16]  N. Dreyer,et al.  The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. , 1999, The American journal of medicine.

[17]  T. Iga,et al.  Sustained QT prolongation induced by tacrolimus in guinea pigs. , 1999, Life sciences.

[18]  G. Talbot,et al.  The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. , 1999, Clinical therapeutics.

[19]  Y. M. Lee,et al.  Comparison of the relative activities of alpha-tocopherol and PMC on platelet aggregation and antioxidative activity. , 1999, Life sciences.

[20]  B. Nørgaard,et al.  Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial , 1999 .

[21]  P. Vardas,et al.  Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. , 1999, Journal of the American College of Cardiology.

[22]  F. D. de Abajo,et al.  Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. , 1999, British journal of clinical pharmacology.

[23]  J. Eriksson,et al.  Life‐threatening ventricular tachycardia due to liquorice‐induced hypokalaemia , 1999, Journal of internal medicine.

[24]  B. Drolet,et al.  Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. , 1999, The Journal of pharmacology and experimental therapeutics.

[25]  D. Flockhart,et al.  Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6) , 1999, Clinical pharmacology and therapeutics.

[26]  B. Nørgaard,et al.  Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. , 1999, American heart journal.

[27]  D. Flockhart,et al.  Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. , 1998, Journal of clinical psychopharmacology.

[28]  A. Katchman,et al.  The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. , 1998, The Journal of pharmacology and experimental therapeutics.

[29]  B. Knollmann,et al.  Cardiac actions of erythromycin: influence of female sex. , 1998, JAMA.

[30]  O. Fraidakis,et al.  Anaesthesia and the QT interval in humans: effects of halothane and isoflurane in premedicated children. , 1998, European journal of anaesthesiology.

[31]  R. Henthorn,et al.  Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. , 1998, American heart journal.

[32]  R. Sorelle.  Withdrawal of Posicor from market. , 1998, Circulation.

[33]  C. Tracy,et al.  QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. , 1998, Transplantation.

[34]  G. Steinbeck,et al.  Effects of Class I drugs on atrial fibrillation. , 1998, Journal of cardiovascular electrophysiology.

[35]  A. Brown,et al.  Blockade of HERG and Kv1.5 by ketoconazole. , 1998, The Journal of pharmacology and experimental therapeutics.

[36]  M. Chung,et al.  Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. , 1998, Journal of the American College of Cardiology.

[37]  H Kratzer,et al.  Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. , 1998, The American journal of cardiology.

[38]  K. Stangl,et al.  Superiority of ibutilide (a new class III agent) overdl-sotalol in converting atrial flutter and atrial fibrillation , 1998, Heart.

[39]  R. Woosley,et al.  Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. , 1998, Journal of women's health.

[40]  C. Berul,et al.  Proarrhythmia associated with cisapride in children. , 1998, Pediatrics.

[41]  D. Roden.  Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes , 1998, Pacing and clinical electrophysiology : PACE.

[42]  P. Kowey,et al.  Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. , 1998, Journal of the American College of Cardiology.

[43]  J. Brachmann,et al.  Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study , 1998, Pacing and clinical electrophysiology : PACE.

[44]  S. Tang,et al.  QT prolongation and Torsades de Pointes associated with clarithromycin. , 1998, The American journal of medicine.

[45]  H. Mohri,et al.  Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia. , 1997, Internal medicine.

[46]  B. Phibbs,et al.  Torsade de pointes and low-dose oral haloperidol. , 1997, Archives of internal medicine.

[47]  M. Sekkarie,et al.  Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  K. Hussain,et al.  A Review of Erythromycin-Induced Malignant Tachyarrhythmia— Torsade de Pointes , 1997, Angiology.

[49]  J. N. Black,et al.  Quinine May Trigger Torsades de Pointes During Astemizole Therapy , 1997, Pacing and clinical electrophysiology : PACE.

[50]  G Duker,et al.  Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? , 1997, The Journal of pharmacology and experimental therapeutics.

[51]  F. Bengtsson,et al.  Symptoms and signs of severe citalopram overdose , 1997, The Lancet.

[52]  S. Nasraway,et al.  Conduction Disturbances Associated with Administration of Butyrophenone Antipsychotics in the Critically Ill: A Review of the Literature , 1997, Pharmacotherapy.

[53]  M. Lindquist,et al.  Risks of non-sedating antihistamines , 1997, The Lancet.

[54]  C. Shapiro,et al.  Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. , 1997, Journal of Clinical Psychopharmacology.

[55]  R. Falk,et al.  Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. , 1997, Journal of the American College of Cardiology.

[56]  H. Persson,et al.  Citalopram overdose--review of cases treated in Swedish hospitals. , 1997, Journal of toxicology. Clinical toxicology.

[57]  C Antzelevitch,et al.  Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. , 1996, Journal of the American College of Cardiology.

[58]  Mark A. Wood,et al.  Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation , 1996 .

[59]  M. Karim,et al.  Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. , 1996, American heart journal.

[60]  J. Anderson,et al.  Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. , 1996, The American journal of cardiology.

[61]  Jeffrey L. Anderson,et al.  Safety and Tolerability of Long-term Propafenone Therapy for Supraventricular Tachyarrhythmias* , 1996 .

[62]  D. Wysowski,et al.  Cisapride and fatal arrhythmia. , 1996, The New England journal of medicine.

[63]  P. Sager,et al.  Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. , 1996, Journal of the American College of Cardiology.

[64]  M. Lehmann,et al.  Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. , 1996, American heart journal.

[65]  G. Talbot,et al.  Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. , 1996, The Journal of antimicrobial chemotherapy.

[66]  J. Soler‐Soler,et al.  Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. , 1996, Journal of the American College of Cardiology.

[67]  T. Barnes,et al.  Electrocardiographic changes in patients receiving neuroleptic medication , 1996, Acta psychiatrica Scandinavica.

[68]  M. Rosenqvist,et al.  Quality of life in octogenarians after valve replacement due to aortic stenosis. A prospective comparison with younger patients. , 1996, European heart journal.

[69]  A. Capucci,et al.  Different pharmacologic treatment for converting recent-onset atrial fibrillation: Evaluation on 377 patients , 1996 .

[70]  N. Kerin,et al.  The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation. , 1996, Archives of internal medicine.

[71]  K. Ellenbogen,et al.  Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. , 1996, Circulation.

[72]  B. Joos,et al.  Penetration of cefuroxime into the cerebrospinal fluid of patients with traumatic brain injury. , 1996, The Journal of antimicrobial chemotherapy.

[73]  W. Amery,et al.  Risk of selected serious cardiac events among new users of antihistamines. , 1995, Clinical therapeutics.

[74]  N. Edvardsson,et al.  Effect of Almokalant, a Selective Potassium Channel Blocker, on the Termination and Inducibility of Paroxysmal Supraventricular Tachycardias: A Study in Patients with Wolff‐Parkinson‐White Syndrome and Atrioventricular Nodal Reentrant Tachycardia , 1995, Journal of cardiovascular pharmacology.

[75]  S. Krähenbühl,et al.  Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. , 1995, The American journal of the medical sciences.

[76]  R. Platt,et al.  Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. , 1995, Annals of epidemiology.

[77]  R. Falk,et al.  Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. , 1995, American heart journal.

[78]  S. Cobbe,et al.  Chemical cardioversion of atrial fibrillation with intravenous dofetilide. , 1995, International journal of cardiology.

[79]  A. Mbewu,et al.  Fluoxetine and ventricular torsade--is there a link? , 1995, International journal of cardiology.

[80]  I. Whyte,et al.  Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. , 1995, Journal of toxicology. Clinical toxicology.

[81]  L A Moyé,et al.  The cardiac arrhythmia suppression trial. Casting suppression in a different light. , 1995, Circulation.

[82]  K. Olree,et al.  Torsade de pointes and elevated magnesium and calcium requirements associated with intravenous pentamidine. , 1994, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[83]  D. Roden.  Risks and benefits of antiarrhythmic therapy. , 1994, The New England journal of medicine.

[84]  M. Viitasalo,et al.  Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome , 1994, Clinical cardiology.

[85]  C. Pratt,et al.  Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. , 1994, The American journal of cardiology.

[86]  B. Gitler,et al.  Torsades de pointes induced by erythromycin. , 1994, Chest.

[87]  S. H. Thomas,et al.  Drugs, QT interval abnormalities and ventricular arrhythmias. , 1994, Adverse drug reactions and toxicological reviews.

[88]  M. Dan,et al.  Erythromycin-associated hypotension. , 1993, The Pediatric infectious disease journal.

[89]  W. Scott,et al.  Pentamidine-induced torsades de pointes. , 1993, The Pediatric infectious disease journal.

[90]  M. Bras,et al.  Prolonged QT interval with halofantrine , 1993, The Lancet.

[91]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[92]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[93]  E. Winer,et al.  High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. , 1992, Journal of the National Cancer Institute.

[94]  R. Kronmal,et al.  Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1992, Journal of the American College of Cardiology.

[95]  A. Capucci,et al.  Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. , 1992, The American journal of cardiology.

[96]  H L Greene,et al.  The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. , 1992, Journal of the American College of Cardiology.

[97]  P. Dunselman,et al.  Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. , 1992, The American journal of cardiology.

[98]  J. Cowan,et al.  Torsades de pointes ventricular tachycardia and terodiline , 1991, The Lancet.

[99]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[100]  C. L. Ferguson,et al.  Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.

[101]  W. Kannel,et al.  Epidemiology of sudden coronary death: population at risk. , 1990, The Canadian journal of cardiology.

[102]  E. Antman,et al.  Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. , 1990, Circulation.

[103]  K. Thygesen,et al.  Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. , 1990, European heart journal.

[104]  N. Edvardsson,et al.  Torsade de pointes tachycardias induced by overdosage of zimeldine. , 1989, Journal of cardiovascular pharmacology.

[105]  V. Harindra,et al.  Cardiotoxic effect with convulsions in terfenadine overdose. , 1989, BMJ.

[106]  A. Pelech,et al.  ASTEMIZOLE-INDUCED TORSADE DE POINTES , 1988, The Lancet.

[107]  E. Aliot,et al.  The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.

[108]  A. Maisel,et al.  Torsades de pointes precipitated by a Chinese herbal remedy. , 1987, The American journal of cardiology.

[109]  P. Guéret,et al.  [Bepridil and torsades de pointes. Apropos of 11 cases]. , 1987, Annales de cardiologie et d'angeiologie.

[110]  T. Peter,et al.  QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. , 1987, The American journal of cardiology.

[111]  F. Casazza,et al.  [Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case]. , 1986, Giornale italiano di cardiologia.

[112]  D. Roden,et al.  Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.

[113]  G. Ducloux,et al.  Nine cases of torsade de pointes with bepridil administration. , 1986, American heart journal.

[114]  W. Kannel,et al.  Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. , 1986, American heart journal.

[115]  M. Callaham,et al.  Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. , 1985, Annals of emergency medicine.

[116]  N. Fineberg,et al.  Prolongation of the QT interval induced by probucol: demonstration of a method for determining QT interval change induced by a drug. , 1984, American heart journal.

[117]  P. Valere,et al.  [Bepridil and torsades de pointes]. , 1983, Archives des maladies du coeur et des vaisseaux.

[118]  H. Herrmann,et al.  Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. , 1983, The American journal of cardiology.

[119]  N. White,et al.  Quinine and Quinidine: A Comparison of EKG Effects During the Treatment of Malaria , 1983, Journal of cardiovascular pharmacology.

[120]  S. Swiryn,et al.  Doxepin Induced Torsade De Pointes , 1982, Pacing and clinical electrophysiology : PACE.

[121]  P. Heinbecker,et al.  Adverse effects of amiodarone. , 1982, JAMA.

[122]  R. Weinstein.  Hypercalcemia and Vitamin D Metabolism-Reply , 1981 .

[123]  L. Klein.  QT-interval prolongation produced by probucol. , 1981, Archives of internal medicine.

[124]  M. Herman,et al.  QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration. , 1981, The Mount Sinai journal of medicine, New York.

[125]  D. Evans,et al.  Long-term results of DC reversion of atrial fibrillation. , 1968, British heart journal.

[126]  G. Cramér.  Early and late results of conversion of atrial fibrillation with quinidine. A clinical and hemodynamic study. , 1968, Acta medica Scandinavica. Supplementum.